Prevalence of Low High-Density Lipoprotein Cholesterol in Patients With Documented Coronary Heart Disease or Risk Equivalent and Controlled Low-Density Lipoprotein Cholesterol

American Journal of Cardiology

Volumn 100, Issue 10, 2007, Pages 1499-1501

  Alsheikh Ali, Alawi A ^a   Lin, Jen Liang ^b   Abourjaily, Paul ^b   Ahearn, Dineli ^b   Kuvin, Jeffrey T ^a   Karas, Richard H ^a  

^a Molecular Cardiology Research Institute   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DECISION MAKING; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TOBACCO DEPENDENCE;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE;

EID: 35748972380     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.058     Document Type: Article

References (8)

1. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
2. ClinicalTrials.gov. Niacin Plus Statin to Prevent Vascular Events. Available at: http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00120289?order=1. Accessed June 13, 2007.
3. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., Dolor R.J., Ganiats T.G., Gomes A.S., Gornik H.L., Gracia C., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
4. Genest Jr. J., McNamara J.R., Ordovas J.M., Jenner J.L., Silberman S.R., Anderson K.M., Wilson P.W., Salem D.N., and Schaefer E.J. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 19 (1992) 792-802
5. Mosca L., Merz N.B., Blumenthal R.S., Cziraky M.J., Fabunmi R.P., Sarawate C., Watson K.E., Willey V.J., and Stanek E.J. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111 (2005) 488-493
6. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count?. Atherosclerosis 180 (2005) 217-223
7. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intenive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
8. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs Jr. D.R., Bangdiwala S., and Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15